0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Brief Communications |

Additional Chenodiol Therapy After Partial Dissolution of Gallstones with Two Years of Treatment

JAY W. MARKS, M.D.; RICHARD A. BAUM, M.D.; RUSSELL F. HANSON, M.D.; THEODORE HERSH, M.D.; N. C. HIGHTOWER Jr, M.D.; HAGOP MEKHJIAN, M.D.; ROBERT A. SCHAEFER, M.D.; ROGER D. SOLOWAY, M.D.; JOHNSON L. THISTLE, M.D.; FRED B. THOMAS, M.D.; and MALCOLM P. TYOR, M.D.
[+] Article and Author Information

Presented in part in May 1982 at the annual meeting of the American Gastroenterological Association; Chicago, Illinois.

▸Requests for reprints should be addressed to Jay W. Marks, M.D.; Division of Gastroenterology, Cedars-Sinai Medical Center, P.O. Box 48750; Los Angeles, CA 90048.


THE NATIONAL COOPERATIVE GALLSTONE STUDY GROUP; Los Angeles, California; Baltimore, Maryland; Minneapolis and Rochester, Minnesota; Atlanta, Georgia; Temple, Texas; Columbus, Ohio; New York, New York; Philadelphia, Pennsylvania; and Durham, North Carolina


© 1984 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1984;100(3):382-384. doi:10.7326/0003-4819-100-3-382
Text Size: A A A

During the National Cooperative Gallstone Study, therapy with chenodiol, 750 or 375 mg/d, for 2 years resulted in confirmed, complete gallstone dissolution in 14% and 5% of patients, respectively, and partial dissolution (> 50%) in 27% and 18%. The present study was done to determine the frequency with which complete dissolution occurs in patients having partial dissolution of gallstones who receive additional therapy. Eighty-six of one hundred thirty-eight eligible patients continued to receive 750 mg/d (61 patients) or 375 mg/d (25 patients) of chenodiol for 1 year. Patients whose oral cholecystogram at the end of the year showed further (> 50%) dissolution continued to receive chenodiol (28 patients at 750 mg/d and 11 patients at 375 mg/d) for a second year (total duration of therapy, 4 years). A final oral cholecystogram was taken at the end of the fourth year. Complete dissolution occurred in 23% and 16% of patients receiving chenodiol, 750 or 375 mg/d, respectively, for an additional 1 or 2 years.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)